Eupraxia Pharmaceuticals (EPRX) Short term Debt (2022 - 2023)
Eupraxia Pharmaceuticals' (EPRX) quarterly Short term Debt came in at $10.3 million in Q4 2023, up 12914.69% year-on-year from N/an in Q4 2022, and up 12914.69% on a QoQ basis from $79418.0 in Q4 2022.
Eupraxia Pharmaceuticals (EPRX) Short term Debt (2022 - 2023) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 2 years of Short term Debt data on file, last reported at $10.3 million in Q4 2023.
- On a quarterly basis, Short term Debt rose 12914.69% year-over-year to $10.3 million in Q4 2023; TTM through Dec 2023 was $10.3 million, a 12914.69% increase from a year earlier, with the FY2023 full-year figure at $10.3 million, up 12914.69% from the prior year.
- Short term Debt for Q4 2023 stood at $10.3 million, up from $79418.0 in the prior quarter.
- Over the last five years, Short term Debt for EPRX reached as high as $10.3 million in Q4 2023 and fell as low as $79418.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 10.34 Mn |
| Dec 31, 2022 | 79,418.00 |